The identification of an endogenous peptide of pleiotrophin as a new AD biomarker demonstrates that the quantification-driven approach enables identification of new biomarkers that lie outside the boundaries of identification-driven analysis. The gene discussed is PTN; the disease is Alzheimer disease.